<DOC>
	<DOCNO>NCT00667810</DOCNO>
	<brief_summary>This study evaluate efficacy safety multiple dos bapineuzumab patient mild moderate Alzheimer Disease . Patients receive either bapineuzumab placebo . Each patient 's participation last approximately 1.5 year .</brief_summary>
	<brief_title>Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Diagnosis probable Alzheimer Disease ( AD ) , Mini Mental State Examination ( MMSE ) score 1626 , brain magnetic resonance imaging ( MRI ) consistent diagnosis AD Concurrent use cholinesterase inhibitor memantine allow , stable Caregiver participate able attend clinic visit patient Significant neurological disease AD Major psychiatric disorder Contraindication undergo brain MRI [ e.g. , pacemaker , cerebrospinal fluid ( CSF ) shunt , foreign metal object body ] Women childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>antibody</keyword>
	<keyword>immunotherapy</keyword>
</DOC>